Cancerimmunterapi til behandling af hæmatologisk cancer

Morten Orebo Holmström, Uffe Klausen, Nicolai Grønne Jørgensen, Staffan Holmberg, Jacob Grauslund, Özcan Met, Inge Marie Svane, Lars Møller Pedersen, Lene Meldgaard Knudsen, Hans Carl Hasselbalch, Mads Hald Andersen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstract

Cancer immune therapy is now used routinely for the treatment of several solid malignancies, albeit just recently having entered the clinic for treatment of haematological malignancies. Several studies demonstrate that cancer immune therapy is a promising treatment modality for the latter. Especially treatment with chimeric antigen receptor T cells for acute lymphoblastic leukaemia and lymphoma is promising. Other promising treatment modalities are immune check point inhibitors for both lymphoid and myeloid malignancies, as well as therapeutic cancer vaccination targeting tumour antigens.

Bidragets oversatte titelCancer immune therapy for the treatment of haematological malignancies
OriginalsprogDansk
ArtikelnummerV06180421
TidsskriftUgeskrift for Laeger
Vol/bind181
Udgave nummer10
Antal sider5
ISSN0041-5782
StatusUdgivet - 2019

Emneord

  • Antigens, Neoplasm
  • Hematologic Neoplasms/therapy
  • Humans
  • Immunotherapy
  • Myeloproliferative Disorders

Citationsformater